Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
lixivaptan (CRTX 080)
Also known as: formerly VPA-985
print preview
bookmark
share with colleague
General Information
Company
Cornerstone Therapeutics Inc.
Description
Selective vasopressin V2 receptor antagonist
Molecular Target
Vasopressin 2 (V2) receptor
Mechanism of Action
Vasopressin 2 (V2) receptor antagonist
Latest Stage of Development
Registration
Indication
Hyponatremia
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy